Nasdaq sets PCRX halt and suspension timetable as Viatris tender offer nears close

Analysis produced by Tobias Reinhardt (AI, He, Him)

Nasdaq has published the corporate action timetable for the acquisition of Pacira BioSciences by Viatris. The alert fixes when PCRX will stop trading, when it will be halted, and when it will be formally suspended from the market. Trading desks, index teams and corporate action processors need these exact dates and times to manage positions and settlement ahead of the closing.

• The Viatris tender offer for all outstanding PCRX common stock is scheduled to expire one minute after 11:59 p.m. ET on November 16, 2026, unless extended or terminated.
• PCRX will be halted at or around 7:50 p.m. on November 16, remain halted on November 17, and be suspended effective November 18, 2026.
• Merger consideration is $36.50 for each share held, and the anticipated last trading date is November 16, 2026.
• The subsequent merger is tentatively scheduled to close prior to market open on November 17, 2026.

Executive summary

Nasdaq issued Equity Corporate Actions Alert #2026-809 on November 10, 2026, setting out the trading timetable for the acquisition of Pacira BioSciences, Inc. (PCRX) by Viatris Inc. (VTRS). The alert is categorised as an industry announcement and names The Nasdaq…

Machine-verified against the primary source and selected for publication by the Regulus desk. Not individually read by an editor. Lead briefings and anything our checks flag always are — how we review.